Myocardial viability: nuclear assessment.
There are an estimated 5 million patients with congestive heart failure (CHF) in the United States. The long-term outcome in these patients is poor with a 5-year mortality of 70%. There is evidence suggesting that revascularization in patients with viable myocardium can result in reduced event rate in these patients. The presence of viable myocardium best identifies patients who will improve with revascularization. Noninvasive imaging with radionuclide tracers has been used extensively to identify the presence and extent of viable myocardium. We have summarized the role of radionuclide myocardial perfusion and function evaluation in assessment of viable myocardium in this review.
Mehta
Deval
D
The Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Iskandrian
Ami E
AE
D019788:Fluorodeoxyglucose F18; D006333:Heart Failure / Q000000981:diagnostic imaging* / Q000503:physiopathology; D006801:Humans; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000503:physiopathology; D009204:Myocardial Revascularization; D019275:Radiopharmaceuticals; D013667:Technetium; D013794:Thallium Radioisotopes; D015899:Tomography, Emission-Computed, Single-Photon
D019275:Radiopharmaceuticals; D013794:Thallium Radioisotopes; D019788:Fluorodeoxyglucose F18; D013667:Technetium